Hemoglobinuria

Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute

...uropean Union in 2007 as a treatment for patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The use ...ris is the first product approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the U.S. and Europe. PNH is a rare, debilitating, and life-threate...

Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting

...liris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with ecul...sis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal hemoglobinuria (PNH) Patients," Dr. Alexander Roeth, et al. Abstract: http://ash.co...

Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)

...ly targets the immune system). Soliris(R), a humanized monoclonal antibody, is approved in the U.S. and Europe as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disease. The company is exploring the use of Soliris(R) as a treatment for patients with other ...

Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

...nounced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a tr...nsufficiency in Patients with Paroxysmal Nocturnal hemoglobinuria (PNH)" Dr. Peter Hillmen et al. -- L...icant Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, Mil...

Hemoglobinuria in Medical Technology

InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobi...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

...is(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis w...mith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 200...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

...) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a limited number of patients with two other rare and severe complement-mediated...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

...s, fatigue and thrombosis with eculizumab treatment in paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2007;110 (11):1072a. (11) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11)...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

...(eculizumab) as a treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The open-label study, which was authorized by Japan's Pharmaceutical..., Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;1...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

...globinuria. N Engl J Med. 2006;355:1233-1243. (3) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):985. (4) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal noc...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

... a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expecte...Significant Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anem...icant Disease Burden in Paroxysmal Nocturnal hemoglobinuria Patients with Lower Levels of Hemolysis, Mil...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times more likely than ...nsufficiency in Patients with Paroxysmal Nocturnal hemoglobinuria (PNH)" and "Sustained Improvements in Transfusion ... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 200...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

...pulation of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), according to an analysis of the Phase III SHEPHERD study published o...tts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11)...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

...he first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening b... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Ba...rebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 pr...

Hemoglobinuria in Medical Products

Paroxysmal Nocturnal Hemoglobinuria Profile-WBC

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories

Paroxysmal Nocturnal Hemoglobinuria Profile-RBC

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories

Hemoglobinuria in Medical Definition

Hematopathology

...ereditary stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis Coagulation / platelets DIC • Hemophili...

Pathology

...ereditary stomatocytosis , Warm autoimmune hemolytic anemia , Hemolytic-uremic syndrome , Microangiopathic hemolytic anemia , Paroxysmal nocturnal hemoglobinuria ) • Aplastic anemia : ( Acquired pure red cell aplasia , Fanconi anemia ) • Hemochromatosis Coagulation / platelets DIC • Hemophili...

Hemoglobinuria in Medical Dictionary

Hemoglobinuria

In medicine, hemoglobinuria is a condition in which the oxygen transport protein hemoglobin is found in abnormally high concentrations in the urine. The condition is often associated with hemolytic anemia, in which red blood cells are destroyed, thereby increasing... This is called ...

Hemoglobinuria in Biological Technology

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

...emolysis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal hemoglobinuria (PNH) Patients" was presented yesterday at the ASH annual meeting by Alexan...tts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11)...

Alexion Reports Third Quarter 2008 Results

...ch 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The Company reports both GAAP operating results and non-GAAP operating results. No...

Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product

...an be found at: http://www.alexionpharm.com . [ALXN-G] (1) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):985. (2) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal nocturnal...

Alexion Reports First Quarter 2008 Results

...ch 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. The Company reports both GAAP results and non-GAAP results. Non-GAAP results are e...

Alexion Reports Fourth Quarter and Full Year 2007 Results

...n March 2007 and the European Commission in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease. A portion of the Soliris product sold in the fourth quarter was previously accounted for...

Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)

...ion during 2007. Soliris(R) (eculizumab) is a complement inhibitor product developed and marketed by Alexion for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease. "Soliris opened a major new therapeutic avenue for patients with PNH, and the scientists...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

...he first therapy approved for paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening b... cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Ba...rebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 pr...